RESEARCH
Bionor Immuno AS focuses on the development of therapeutic and preventative vaccines targeting infectious diseases and cancer. Highly specific peptide design and intradermal delivery allow for optimum presentation of the peptides to the immune system. The immune responses generated are specific for the target pathogen and aim to induce and/or enhance sustainable immune responses to viral antigens. Bionor Immuno is developing peptide vaccine antigens that aim to stimulate cell-mediated immunity (to remove infected cells) and /or induce non-neutralizing antibodies (humoral immunity) that can modulate disease progression.
Area of focus Peptide Design Peptide Delivery
home about us pipeline investors research news events careers sitemap contact© 2008 BionorImmuno, Inc. All rights Reserved
ABOUT US PIPELINE RESEARCH NEWS SITEMAP CONTACT US EVENTS CAREERS HOME INVESTORSBionor Immuno AS, a subsidary of Bionor Pharma ASA was established on July 14th 2000 as a spin off from the R&D on immune based therapies that until then had been performed by its sister company, Bionor AS. Both companies are located at the Telemark Biomedical Centre, Skien, Norway together with two of its development partners AS Telelab and Mericon AS.